Avita Medical Appoints Dr. Michael Tarnoff to Board

The latest announcement is out from Avita Medical ( (RCEL) ).

On August 6, 2025, AVITA Medical announced the appointment of Dr. Michael Tarnoff to its Board of Directors, highlighting his extensive leadership experience in medical innovation. This strategic move aims to bolster AVITA’s focus on advancing patient-centric wound-healing technologies and expanding its presence in hospitals and trauma care settings. Additionally, Cary Vance has been elected as the new Board Chair, succeeding Lou Panaccio, who was thanked for his decade-long service. These changes reflect AVITA’s commitment to innovation and growth within the therapeutic acute wound care industry.

The most recent analyst rating on (RCEL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.

Spark’s Take on RCEL Stock

According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.

Avita Medical’s stock score reflects a blend of strong revenue growth and technical momentum, offset by severe profitability challenges and high financial leverage. While future revenue projections and product expansions are promising, underlying financial weaknesses and valuation concerns present significant risks.

To see Spark’s full report on RCEL stock, click here.

More about Avita Medical

AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery. Their flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient’s skin to create Spray-On Skin Cells for improved clinical outcomes. AVITA also holds exclusive rights to market and distribute PermeaDerm and Cohealyx in the U.S., and the RECELL System is approved for various applications internationally.

Average Trading Volume: 315,721

Technical Sentiment Signal: Sell

Current Market Cap: $139.6M

See more data about RCEL stock on TipRanks’ Stock Analysis page.